10X Capital Venture Acquisition Corp. III
VCXB
New York Stock Exchange11.07
USD
-0.93
- -
CIK
0001848948
ISIN
KYG870771063
CUSIP
G87077106
Return %
Stock
S&P500
1Y
5.03
26.53
3Y
11.26
76.60
5Y
11.26
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David Weisburd
- Full Time Employees
- 4
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1 World Trade Center New York City NY United States of America 10007
- IPO Date
- Mar 4, 2022
- CIK
- 0001848948
- Website
- 10xspac.com
- Similar Companies
- Business
- 10X Capital Venture Acquisition Corp. III (NYSE American: VCXB; VCXB.U; VCXB WS) operates as a blank check company whose purpose centers on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company targets high-growth technology and tech-enabled businesses globally in sectors including consumer internet; ecommerce; software; healthcare; transportation and mobility; financial services; as well as industries disrupted by artificial intelligence, automation, data science, and Software-as-a-Service. Sponsored by 10X Capital, an alternative asset management firm that employs data analytics and AI across asset classes, 10X Capital Venture Acquisition Corp. III completed its initial public offering in January 2022, raising $300 million, with headquarters in New York, New York. The company focuses on bringing institutional capital to high-growth ventures in private and public markets, with operations spanning domestic and international geographies; its sponsor maintains commitments to diversity, equity, and inclusion as one of the most active global venture capital firms. In recent developments, 10X Capital Venture Acquisition Corp. III entered a merger agreement in August 2023 with American Gene Technologies International Inc. (AGT), a clinical-stage gene therapy firm developing HIV treatments, valuing AGT at a $500 million pre-money enterprise value plus up to $300 million in earnouts tied to clinical and pricing milestones; the deal included a non-binding $50 million committed equity facility letter of intent with a Cantor Fitzgerald affiliate and anticipated closing in the first quarter of 2024, with the combined entity to relist as Addimmune. Subsequently, the merger with AGT terminated mutually on June 21, 2024, extinguishing related ancillary agreements and extending the deadline for an initial business combination to July 14, 2024; earlier pursuits included a non-binding letter of intent with Sparks Energy, Inc. for a power infrastructure recovery services merger at a $475 million pro forma enterprise value, and a prior leadership change occurred in January 2024 with Hans Thomas departing as Chief Executive Officer while retaining the Chairman role. In October 2023, the company transferred its Class A ordinary shares, redeemable warrants, and units from the New York Stock Exchange to NYSE American LLC for more favorable listing standards, followed by NYSE American's June 2024 initiation of delisting proceedings for its warrants (VCXB WS) due to low trading prices, suspending their trading while shares and units continued. SPAC Research lists the company as liquidated following an amendment vote on July 12, 2024, and closing on July 26, 2024, with CEO David Weisburd overseeing operations underwritten by Cantor Fitzgerald; no successful business combination materialized within its extended 12+9+9 month tenor.
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of 10X Capital Venture Acquisition Corp. III (VCXB WS)
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K Filing
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Noncompliance
10X Capital Venture Acquisition Corp. III Announces Expected Change in Management
10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-Q Filing
10X Capital Venture Acquisition Corp. III Announces Transfer of Listed Securities to the NYSE American
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III